

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived Gln27-Ala349 Accession # Q5M8T4
N-terminal Sequence Analysis	No results obtained. Gln27 inferred from enzymatic pyroglutamate treatment revealing Asn28
Predicted Molecular Mass	35 kDa


SPECIFICATIONS

SDS-PAGE	35-45 kDa, reducing conditions
Activity	Measured by its ability to mediate Balb/3T3 mouse embryonic fibroblast cell adhesion. Ball, D.K. <i>et al.</i> (2003) <i>Reproduction</i> 125 :271. The ED ₅₀ for this effect is 1.5-7.5 µg/mL. Also measured by its ability to induce C2C12 mouse myoblast cells proliferation.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 500 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

Connective Tissue Growth Factor (CTGF), also known as CCN2, is a 36-38 kDa member of the CCN (CYR61/CTGF/NOV) family of secreted matricellular proteins (1). Like other CCN proteins, mature human CTGF consists of IGF-binding protein domain, a vWF-C domain, a TSP-1 domain, and a cysteine knot heparin-binding domain (2). Human CTGF shares 94% amino acid (aa) sequence identity with mouse and rat CTGF. Alternative splicing generates an additional isoform with a 27 aa deletion within the TSP-1 domain. CTGF promotes cell adhesion through interactions with a range of cell surface molecules including heparan sulfate proteoglycans (HSPG), LRPAP, and Integrins α M, α V β 3, α 6 β 1, α 1b β 3 (3-7). It also binds to and regulates signaling through the Wnt receptors LRP6 and Frizzled-8 and the NGF receptors TrkA and NGF R (8, 9). In addition, CTGF binds directly to BMP-4, TGF- β 1, TGF- β 2, and VEGF 165 (10, 11). It blocks BMP-4 and VEGF induced responses but enhances TGF- β induced responses (10-13). Within VEGF complexes, CTGF can be degraded by a variety of proteases, resulting in restoration of angiogenic activity (11). CTGF promotes fibroblast differentiation from mesenchymal stem cells and their production of type I Collagen and Tenascin C (5, 14). It promotes chondrocyte proliferation and cartilage matrix synthesis (15-17). CTGF is expressed in vascular mural and endothelial cells (EC) during development and promotes pericyte-EC association and angiogenesis (2, 17, 18, 19). It is expressed in the cerebral cortex and olfactory bulb and plays an important role in nervous system development (8, 12).

References:

1. Hall-Glenn, F. and K.M. Lyons (2011) *Cell. Mol. Life Sci.* **68**:3209.
2. Bradham, D.M. *et al.* (1991) *J. Cell Biol.* **114**:1285.
3. Gao, R. and D.R. Brigstock (2004) *J. Biol. Chem.* **279**:8848.
4. Schober, J.M. *et al.* (2002) *Blood* **99**:4457.
5. Heng, E.C.K. *et al.* (2006) *J. Cell Biochem.* **98**:409.
6. Jedsadayanmata, A. *et al.* (1999) *J. Biol. Chem.* **274**:24321.
7. Gao, R. *et al.* (2003) *Hepatol. Res.* **27**:214.
8. Mercurio, S. *et al.* (2004) *Development* **131**:2137.
9. Wahab, N.A. *et al.* (2005) *J. Am. Soc. Nephrol.* **16**:340.
10. Abreu, J.G. *et al.* (2002) *Nat. Cell Biol.* **4**:599.
11. Hashimoto, G. *et al.* (2002) *J. Biol. Chem.* **277**:36288.
12. Khodosevich, K. *et al.* (2013) *Neuron* **79**:1136.
13. Shi-Wen, X. *et al.* (2006) *J. Biol. Chem.* **281**:10715.
14. Lee, C.H. *et al.* (2010) *J. Clin. Invest.* **120**:3340.
15. Canalis, E. *et al.* (2010) *Endocrinology* **151**:3490.
16. Nakanishi, T. *et al.* (2000) *Endocrinology* **141**:264.
17. Ivkovic, S. *et al.* (2003) *Development* **130**:2779.
18. Hall-Glenn, F. *et al.* (2012) *PLoS One* **7**:e30562.
19. Shimo, T. *et al.* (1999) *J. Biochem.* **126**:137.